FMP
Inozyme Pharma, Inc.
INZY
NASDAQ
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
2.99 USD
0.18 (6.02%)
About
ceo
Dr. Douglas A. Treco Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.inozyme.comexchange
NASDAQ
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
CIK
0001693011
ISIN
US45790W1080
CUSIP
45790W108
Address
321 Summer Street
Phone
857 330 4340
Country
US
Employee
59
IPO Date
Jul 24, 2020
Key Executives
